scholarly journals Chidamide and mitomycin C exert synergistic cytotoxic effects against bladder cancer cells in vitro and suppress tumor growth in a rat bladder cancer model

2022 ◽  
Author(s):  
Shao-Chuan Wang ◽  
Chia-Ying Yu ◽  
Yao-Cheng Wu ◽  
Ya-Chuan Chang ◽  
Sung-Lang Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Mitomycin C ◽  
Cancer Model ◽  
Cytotoxic Effects ◽  
Rat Bladder ◽  
Bladder Cancer Cells ◽  
Bladder Cancer Model

In vitro and in vivo effects of HAL on porphyrin production in rat bladder cancer cells (AY27)

2019 ◽  
Vol 23 (07n08) ◽  
pp. 813-820
Author(s):  
Odrun A. Gederaas ◽  
Harald Husebye ◽  
Anders Johnsson ◽  
Susan Callaghan ◽  
Anders Brunsvik
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix ◽  
Active Agent ◽  
Laser Scanning Microscopy ◽  
Rat Bladder ◽  
Bladder Cancer Cells

Aminolevulinic acid and hexyl-aminolevulinate serve as biological precursors to produce photosensitive porphyrins in cells via the heme biosynthetic pathway. This pathway is integral to porphyrin-based photodynamic diagnosis and therapy. By adding exogenous hexyl-aminolevulinate to rat bladder cancer cells (AY27, in vitro) and an animal bladder cancer model (in vivo), fluorescent endogenous porphyrin production was stimulated. Lipophilic protoporphyrin IX was identified as the dominant species by reverse high-pressure liquid chromatography. Subcellular porphyrin localization in the AY27 cells was evaluated by confocal laser scanning microscopy and showed almost quantitative bleaching after 20 s. From this study, we ascertained that the protocol described herein is suitable for hexyl-aminolevulinate-mediated photodynamic therapy and diagnosis when protoporphyrin IX is the active agent.

scholarly journals Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model

2018 ◽  
Vol 10 (7) ◽  
pp. 213-221 ◽  
Author(s):  
F. Johannes P. van Valenberg ◽  
Dalit Strauss-Ayali ◽  
Yael Agmon-Gerstein ◽  
Astar Friedman ◽  
Harm C. Arentsen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Drug Release ◽  
Mitomycin C ◽  
Current Model ◽  
Clinical Signs ◽  
Surrogate Marker ◽  
Release Mechanism ◽  
Cancer Model ◽  
Rat Bladder ◽  
Bladder Cancer Model

Background: We investigated a thermoreversible hydrogel that is highly viscous at body temperature, while fluid-like at a low temperature, thus aiming for a slow and prolonged intravesical drug release. Our study purposed to assess antitumor efficacy of mitomycin C (MMC) mixed with hydrogel in an orthotopic rat bladder cancer model. Methods: Bladders of female Fischer F344 rats were grafted with 1.5 × 106 AY-27 urothelial carcinoma cells. On day 5, tumor presence was assessed by cystoscopy and rats were divided into six groups (five treatment, one control, n = 10/group). Intravesical treatments (0.5 mg or 1 mg MMC-H2O or MMC-hydrogel, or 2 mg MMC-hydrogel) were administered on days 5, 8 and 11. Rats were sacrificed at day 14 and bladders were evaluated. Results: Rats with tumor at cystoscopy (47/60) were evaluated for efficacy. At necropsy, all control animals (8/8) had tumors. No microscopic tumors were present in the 0.5 mg and 1 mg MMC-hydrogel groups compared with 2/8 and 1/8 rats in the 0.5 mg and 1 mg MMC-H2O groups ( p = 0.47 and p = 1.00, respectively). Greater toxicity was seen in animals treated with MMC-hydrogel compared with MMC-H2O, as demonstrated by lower body weights at necropsy ( p = 0.000) and a tendency for more severe clinical signs in the 1 and 2 mg MMC-hydrogel groups. Rats that died prematurely received 1 mg (4/10) or 2 mg (9/10) of MMC-hydrogel. Conclusions: Under the current model conditions it is unclear whether instillation of MMC-hydrogel is more effective than MMC-H2O. Nonetheless, the observed difference in toxicity, acting as a surrogate marker for systemic MMC exposure in the MMC-hydrogel-treated rats, supports the prolonged drug release mechanism of the hydrogel.

Magrolimab and gemcitabine-cisplatin combination enhance phagocytic elimination of bladder cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e17035-e17035
Author(s):  
Bernhard Kiss ◽  
Anne Kathrin Volkmer ◽  
Dongdong Feng ◽  
Kelly Marie McKenna ◽  
Shirley Mihardja ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Growth ◽  
Cancer Cells ◽  
In Vivo Studies ◽  
Experimental Setup ◽  
Nsg Mice ◽  
Bladder Cancer Cells ◽  
Urothelial Bladder

e17035 Background: CD47 is an antiphagocytic signal and macrophage checkpoint that bladder and other cancer cells over-express to evade innate immunity. Magrolimab (Hu5F9-G4) a CD47 blocking antibody, promotes phagocytosis of cancer cells by macrophages and is being tested in several clinical trials (NCT02953509, NCT03248479, NCT02953782, NCT03558139). Chemotherapies synergize with magrolimab by increasing “eat me” signals on cancer cells, and thus enhancing phagocytosis. This synergy has been shown in MDS and AML, whereby magrolimab+azacitidine has shown encouraging efficacy in pre-clinical and clinical studies. This study aimed to investigate the effect of magrolimab as monotherapy and in combination with gemcitabine-cisplatin chemotherapy in bladder cancer. Methods: Phagocytosis of urothelial bladder cancer cells (639V) was evaluated in vitro with magrolimab alone and in combination with chemotherapy (gemcitabine + cisplatin). Treatment in vivo was evaluated in a xenograft mouse model. 639V cells were transplanted into NSG mice and upon confirmation of engraftment mice were randomized into 4 treatment cohorts: control (PBS), magrolimab, chemotherapy (cisplatin + gemcitabine), and magrolimab in combination with chemotherapy. In the first experimental setup treatment was started early in small tumors and in the second experimental setup treatment was started late after tumors have grown to large size. Tumor growth was monitored by in vivo bioluminescent imaging. Metastases were evaluated postmortem. Results: Chemotherapy increased calreticulin on bladder cancer cells. Magrolimab enhanced phagocytosis of bladder cancer cells in vitro and combination of magrolimab with chemotherapy further increased phagocytosis compared to either therapy alone. Magrolimab and chemotherapy, each alone decreased tumor growth in vivo but only combination of magrolimab with chemotherapy showed a strong inhibition of tumor growth, resulting in a significantly prolonged survival compared to all other treatment cohorts. This was shown for both, small tumors and large tumors. Metastases formation in liver and lungs was completely inhibited by treatment with magrolimab, whereas mice treated with chemotherapy alone or PBS control showed metastases in these organs. Conclusions: Magrolimab treatment in combination with chemotherapy was efficacious in preclinical in vitro and in vivo studies in bladder cancer and provides a novel treatment opportunity for patients with bladder cancer and other solid tumors.

In vitro and in vivo effects of HAL on porphyrin production in rat bladder cancer cells (AY27)

2021 ◽  
pp. 302-309
Author(s):  
Odrun A. Gederaas ◽  
Harald Husebye ◽  
Anders Johnsson ◽  
Susan Callaghan ◽  
Anders Brunsvik
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Rat Bladder ◽  
Bladder Cancer Cells ◽  
In Vivo Effects

scholarly journals Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo

Molecules ◽  
2020 ◽  
Vol 25 (14) ◽  
pp. 3271
Author(s):  
Nada Oršolić ◽  
Dyana Odeh ◽  
Maja Jazvinšćak Jembrek ◽  
Jelena Knežević ◽  
Darko Kučan
Keyword(s):  
Bladder Cancer ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Combined Treatment ◽  
Short Term ◽  
In Vivo Models ◽  
Short Term Exposure ◽  
Bladder Cancer Cells

Quercetin (QU), a hyperthermic sensitizer, when combined with cisplatin (CP) affects tumor growth. To determine the effects of QU and CP and their interactions, multimodal treatment in vitro and in vivo models under physiological and hyperthermic conditions was performed. In vitro, different sensitivity of T24 and UMUC human bladder cancer cells was observed after short-term exposure to QU (2 h) and CP (1 h). Effects of both compounds were investigated at low and high micromolar concentrations (1 and 50 µM, respectively) under both thermal conditions. QU acted in additive or synergistic manner in combination with CP between physiological condition and hyperthermia. As determined by 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, short-term application of QU and CP reduced cell viability. Clonal assay also indicated that combined treatment with QU and CP is lethal to bladder cancer cells in both conditions. In vivo, CP (5 or 10 mg kg−1) and QU (50 mg kg−1) acted synergistically with hyperthermia (43 °C) and inhibited tumor growth, activated immune effectors and increased mice survival. Our results demonstrate that combined treatment with CP and QU may increase death of tumor cells in physiological and hyperthermic conditions which could be clinically relevant in locoregional chemotherapy.

scholarly journals Changes in Tumor Growth and Metastatic Capacities of J82 Human Bladder Cancer Cells Suppressed by Down-Regulation of Calreticulin Expression

2011 ◽  
Vol 179 (3) ◽  
pp. 1425-1433 ◽  
Author(s):  
Yi-Chien Lu ◽  
Chiung-Nien Chen ◽  
Bojeng Wang ◽  
Wen-Ming Hsu ◽  
Szu-Ta Chen ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Tumor Growth ◽  
Cancer Cells ◽  
Human Bladder Cancer ◽  
Down Regulation ◽  
Human Bladder ◽  
Bladder Cancer Cells ◽  
Human Bladder Cancer Cells

SYSTEMATIC IN VITRO EVALUATION OF SURVIVIN DIRECTED ANTISENSE OLIGODEOXYNUCLEOTIDES IN BLADDER CANCER CELLS

2004 ◽  
Vol 171 (6 Part 1) ◽  
pp. 2471-2476 ◽  
Author(s):  
SUSANNE FUESSEL ◽  
BERND KUEPPERS ◽  
SHUANGLI NING ◽  
MATTHIAS KOTZSCH ◽  
KAI KRAEMER ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Cancer Cells ◽  
Antisense Oligodeoxynucleotides ◽  
In Vitro Evaluation ◽  
Bladder Cancer Cells
Sign in / Sign up

Export Citation Format

Share Document